Chemical proteomics is emerging as a powerful pre-clinical component for the identification and validation of novel drug targets. A substantial challenge in probing biological systems remains the identification of targets being perturbed and causing favorable phenotypic response. Critical to the success of discovery programs is the challenging aspect of DE convoluting targets and pathways elucidating the mechanism of action of chemical compounds. Advances in chemical proteomics and quantitative mass spectrometry, introducing high-throughput workflows for target DE convolution, disease pathway analysis and understanding cellular protein dynamics, have recently improved pre-clinical target validation.
Related Journals of Chemical Proteomics:
Journal of Proteome Research, Cellular and Molecular Proteomics, Proteome Science, European Journal of Medicinal Chemistry,